- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FCS Pharmacists in the Front-Line Fight Against Cancer
Florida Cancer Specialists physicians discuss why teamwork is essential to ensure that oncologic pharmaceuticals are used safely and effectively so that patients achieve optimal clinical outcomes.
Delivered by infusions, injections, or taken orally, it takes a range of specially trained professionals working together to ensure that oncologic pharmaceuticals are used safely and effectively so that patients achieve optimal clinical outcomes.
Rx To Go, Florida Cancer Specialists' (FCS') centralized specialty pharmacy based in Fort Myers, Florida, has ready access to 99% of the available oral oncolytics, and can quickly dispense medications and supplies directly to patient homes.
Rx To Go team members, including Stephanie Sabillon, CSPT, CPhT, Kara Sammons, MSPharmReg, CPhT, RPhT, and Rebecca Garland, RPhT, coordinate insurance claims and even make connections to financial assistance programs. But those are just the beginning steps of a vital partnership.
“Our team shares a deep commitment to the mission of pharmacy operations,” said Sabillon, who is the associate director of Pharmacy Operations at FCS. “We align ourselves to ensure the safest, most effective, and cost-sensitive use of pharmaceuticals while promoting safe practices for our patients.”
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
